Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Zillow Group Inc Class A — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.59 (market cap $6.04B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Iovance Biotherapeutics Inc. Common Stock and Zillow Group Inc Class A are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Zillow Group Inc Class A for 86 Days on average.
| IOVA | ZG | |
|---|---|---|
Market Cap | $6.04B | $6.59B |
Volume | 14,805,993 | 1,361,381 |
Sector | Health | Media |
52-Week High | $14.82 | $74.58 |
52-Week Low | $1.81 | $27.70 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $5.97B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zillow Group (ZG) trades at $29.53, up 5.58% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported a return to profitability in 2025 with net income of $23 million, and revenue is projected to grow to $2.8 billion in 2026. Recent news highlights the company's focus on AI integration and a challenging housing market environment.
The outlook is cautiously optimistic, with a consensus price target of $48.87 suggesting significant upside. Key opportunities include revenue growth and market share gains, while risks involve housing market volatility and intense competition. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
